Investigator-led study funded by Glaucoma UK and the HSC R&amp;D Division expands ART27.13’s clinical potential into ophthalmology  Initial DREAM Study Results Anticipated in Q4 2026  SOLANA BEACH, Calif., Aug.  10,

ARTL

Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma

Artelo's ART27.13 Enters Glaucoma DREAM Trial; Results Expected in Q4 2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Investigator-led study funded by Glaucoma UK and the HSC R&amp;amp;D Division expands ART27.13’s clinical potential into ophthalmology  Initial DREAM Study Results Anticipated in Q4 2026  SOLANA BEACH, Calif., Aug.  10,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Artelo Biosciences reports a first patient dosed in the DREAM Phase 2 glaucoma study of ART27.13, expanding its peripherally selective cannabinoid program into eye health. The fully funded trial, led by Queen&#039;s University Belfast researchers and supported by Glaucoma UK and HSC R&amp;D, targets intraocular pressure reduction with limited CNS exposure, with initial results expected in Q4 2026.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Artelo&#039;s ART27.13 dosed in DREAM glaucoma trial; Q4 2026 results anticipated.</li><li>DREAM funded by Glaucoma UK and HSC R&amp;D; led by Prof. Azuara-Blanco.</li><li>ART27.13 is peripherally selective, oral cannabinoid receptor agonist that lowers IOP.</li><li>First patient enrolled; DREAM aims to show safety/tolerability with ocular IOP reduction.</li><li>CAReS data show +6% weight gain at 1300 µg in cancer anorexia cachexia; context.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Artelo Biosciences (ARTL)</strong>: Primary focus; DREAM glaucoma trial marks potential expansion of ART27.13 into ophthalmology.</li><li><strong>Glaucoma UK (N/A)</strong>: Fully funds the DREAM study; adds validation and credibility to ART27.13 program.</li><li><strong>HSC R&amp;D Division (N/A)</strong>: Co-funder of DREAM; supports translational ophthalmology research partnering with ART27.13.</li><li><strong>Belfast Health and Social Care Trust (N/A)</strong>: Sponsor of the DREAM trial; helps ensure robust, clinically anchored study.</li><li><strong>Northern Ireland Clinical Trials Unit (N/A)</strong>: Conducting the DREAM study; adds academic rigor and trial execution credibility.</li><li><strong>Queen&#039;s University Belfast (N/A)</strong>: Lead clinical investigators; high-profile ophthalmology research leadership guiding DREAM.</li><li><strong>AstraZeneca (AZN)</strong>: Original developer of ART27.13; historical context for mechanism and prior clinical work.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Category fits Industry News: drug-development milestone with a potential pathway to ophthalmology; catalyzes ARTL&#039;s valuation if read as validation of ART27.13&#039;s peripheral CB1/CB2 approach.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>DREAM study first patient dosed; potential near-term price movement.</li><li>Initial DREAM results expected in Q4 2026; catalyst window for ARTL.</li><li>Funders and academic leadership add credibility; lowers perceived trial risk.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ART27.13 is an orally administered, peripherally selective CB1/CB2 agonist targeting intraocular pressure.</li><li>First patient dosed in DREAM glaucoma study; initial results anticipated in Q4 2026.</li><li>DREAM is funded by Glaucoma UK and the HSC R&amp;D Division; NI Clinical Trials Unit conducting.</li><li>CAReS Phase 2 data show +6% weight gain at 1300 µg over 12 weeks; placebo −5%.</li><li>Glaucoma is a leading cause of irreversible blindness; affects &gt;80 million people worldwide.</li><li>ART27.13 dosing in glaucoma Phase 2 cited at 650 µg daily.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Trading thesis: If DREAM yields meaningful IOP reduction, ARTL could rally in Q4 2026 on glaucoma expansion.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><em>Investigator-led study funded by Glaucoma UK and the HSC R&amp;D Division expands ART27.13’s clinical potential into ophthalmology</em></p>  <p align="center"><em>Initial DREAM Study Results Anticipated in Q4 2026</em></p>  <p align="left">SOLANA BEACH, Calif., Aug.  10, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3-nE1NubxB_LqKdPRnf3OpBKvm68-lNr6S4y7mFTeTrfIz3cD9SZo-VO_YJ7opkfeqK6WxfH90SxjXqXDv64C89Plpp3mbhqhNe9S3YF1QNNjMrNv1UP09vffb7Xln-f8_l_Tx4krdpIQ8-_3vjd2GDLO2wfEb8Z9UatPcGvpJPziCyOVAjEOMnjl4kxr-pJASWhMbQh2IOvafLrxQR3J6ubXHY1uHJkx2E0FjxdZu3RwFqcXBfFT_8SSNKkw5CTTKfXEyBvrthmgHrkUIMMNQ==" rel="nofollow" target="_blank">Artelo Biosciences, Inc.</a><strong> (Nasdaq: ARTL)</strong>, a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the first patient has been dosed in the DREAM study (<strong>D</strong>etermining the <strong>R</strong>ole of synthetic cannabinoids in <strong>E</strong>ye pressure <strong>A</strong>nd tolerability <strong>M</strong>easurements), which will evaluate the effects of Artelo’s orally administered synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.</p>  <p align="left">ART27.13, a peripherally selective synthetic cannabinoid receptor agonist, represents a novel therapeutic approach aimed at modulating intraocular pressure (IOP) through activation of cannabinoid receptors located in ocular tissues.</p>  <p align="left">Funding for the DREAM study is being provided by Glaucoma UK and the <a href="https://www.globenewswire.com/Tracker?data=uMinBpmETzk4PEtx0ff846Uy2QoTQ8Ogc3WtzotUh-VNplWSf_pf-RPlWrboKzpoNf-tLbgMUP42Gh6ovwWhjsu7ETKDJ1KAzeIC9RBMDTWdnf0n2Esugms_7-oJ1J3Xeo1wWykbmRUfGoMd8V5RYqmNLbAGy9c30zI9aEZ3sXcY0eTR6ah2OzRM5VkwfgjedwnrSPZCVJ7l4i5vtQP62-G4K7gz4f0fF7nQWILMVH1tPldKsZiyP0704ZQjq4-Ia3ADIUxpf5CxtLxEvKxZOQ==" rel="nofollow" target="_blank"><em>HSC R&amp;D Division</em></a>. The study is sponsored by the Belfast Health and Social Care Trust and is being conducted by the Northern Ireland Clinical Trials Unit. Clinical Professor of Ophthalmology at Queen’s University Belfast and Honorary Consultant Ophthalmologist at Belfast Health and Social Care Trust, Professor Augusto Azuara-Blanco, a globally recognized authority in glaucoma management and clinical research, is leading the DREAM study.</p>  <p align="left">"There remains an urgent need for safe, well-tolerated, and effective new treatments for glaucoma that can provide additional options to reduce intraocular pressure and preserve vision," said Professor Azuara-Blanco. "The potential role of peripherally selective cannabinoids in ocular health is an exciting and largely unexplored area. This study is expected to provide important insights into whether ART27.13, which is designed to act outside the central nervous system, can safely lower intraocular pressure without psychotropic side effects."</p>  <p align="left">Glaucoma is a leading cause of irreversible blindness, affecting more than 80 million people worldwide. Elevated IOP is the primary modifiable risk factor for glaucoma progression, but existing therapies—mostly topical eye drops—often face limitations related to adherence, local tolerability, and long-term efficacy.</p>  <p align="left">"We are excited to announce this fully funded Phase 2 clinical study, evaluating ART27.13 in glaucoma, has enrolled its first patient," said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. "The DREAM study has the potential to demonstrate whether an orally active cannabinoid has a role in managing intraocular pressure. ART27.13’s peripherally selective design may overcome the challenges of CNS adverse effects which has been an issue when other oral or topical cannabinoids have been explored in this indication. We are looking forward to announcing initial results from the DREAM study later this year."</p>  <p align="justify"><strong>About ART27.13</strong><br></br>ART27.13 is a novel benzimidazole derivative and dual cannabinoid agonist. Initially developed by AstraZeneca plc, ART27.13 has been in seven clinical studies with over 280 participants. It is being developed as a once-daily, orally administered agent selectively targeting peripheral CB<sub>1</sub> and CB<sub>2</sub> receptors, with the potential to reduce muscle degeneration while improving body weight, appetite, and quality of life in cancer patients. A statistically significant and dose-dependent increase in body weight was observed in people with back pain who were otherwise healthy. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Artelo is conducting a Phase 2 named the Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Interim Phase 2 data revealed patients who had lost at least 5% of body weight to be included in CAReS and titrated to the highest ART27.13 dose (1300 µg) achieved an average +6% weight gain over 12 weeks, while patients on placebo lost an additional ~5%. Currently, there is no FDA approved treatment for cancer anorexia cachexia syndrome. In addition to CAReS, ART27.13 is also being evaluated in a Phase 2 study in people with glaucoma at a daily dose of 650 µg.</p>  <p align="justify"><strong>About Artelo Biosciences</strong><br></br>Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at <a href="https://www.globenewswire.com/Tracker?data=LJ8PWB6E9EtK9c5JwAEdxldN7sR3OM18AdNMi4GU31QJ11c6kxdgbwTd-OhsN4W4W2RYNBirhN9Ukmo1cQmjbnd8AQN606Z8PVXAkVxbA-vRJ1_cnn_-RCWqfazVmsWK1W8e_wzGl5b5yRUe_7JHToxREycyP059lf95yaEE2h8mOH_ifOlEZZHutXZCEHBg4isQrSYaq2ATsDUkPLINVP0dVEuv21Uhd0zHNrwYzTB6hLk-AjQyXK_d72Maqaqok6ZYUieFPaJox-p5GxzFVA==" rel="nofollow" target="_blank">www.artelobio.com</a> and X: @ArteloBio.</p>  <p align="justify"><strong>Forward-Looking Statements</strong><br></br><em>This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.</em></p>  <p align="justify"><strong>Investor Relations Contact:</strong><br></br>Crescendo Communications, LLC<br></br>Tel: 212-671-1020<br></br>Email: ARTL@crescendo-ir.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNjU1NyM3NzY2ODU4IzIxODc1NzA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OGI4MDMzNGMtZjgzZi00ZjUzLTk5YTEtNzI5ZWMzNjA3OWM2LTExOTkxMjMtMjAyNi0wOC0xMC1lbg==/tiny/Artelo-Biosciences.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/460502d7-b0d3-43d8-a15a-5b2bb963bbbb"><img src="https://ml.globenewswire.com/media/460502d7-b0d3-43d8-a15a-5b2bb963bbbb/small/artelo-jpg.jpg" border="0" width="150" height="66" alt="Primary Logo"></img></a></p>

Artelo Biosciences reports a first patient dosed in the DREAM Phase 2 glaucoma study of ART27.13, expanding its peripherally selective cannabinoid program into eye health. The fully funded trial, led by Queen's University Belfast researchers and supported by Glaucoma UK and HSC R&D, targets intraocular pressure reduction with limited CNS exposure, with initial results expected in Q4 2026.

News insight

Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma

AI summary

Sentiment rationale

Key facts

Industry News